Fig. 6
Comparison of tumor inhibition and irAE severity caused by tbLN-directed PD1 and CTLA4 blockade in a unilaterally inoculated mouse model. A. Normalized SiLN luciferase activity (Control, n = 12; anti-PD1, n = 6; anti-CTLA4, n = 6) B. ex vivo luciferase activity of the SiLN, PALN, liver and lung as measured on day 42 post tumor inoculation. (Control, n = 12; anti-PD1, n = 7; anti-CTLA4, n = 6) C. SiLN/body weight at pre-determined experimental endpoint (No tumor control, n = 12; Control, n = 6; anti-PD1, n = 9; anti-CTLA4, n = 8) D. Complete response rates (Control, n = 12; anti-PD1, n = 7; anti-CTLA4, n = 6) E. Survival plots (Control, n = 20; anti-PD1, n = 13; anti-CTLA4, n = 14) E. Severity index of different irAEs (Interstitial pneumonia: No tumor control, n = 17; Control, n = 20; anti-PD1, n = 11; anti-CTLA4, n = 11; Glomerulonephritis and Vasculitis: No tumor control, n = 17; Control, n = 13; anti-PD1, n = 11; anti-CTLA4, n = 11; Sialadenitis: No tumor control, n = 17; Control, n = 13; anti-PD1, n = 8; anti-CTLA4, n = 9). Statistical analyses were done using ANOVA with Tukey’s test. Log-rank (Mantel-Cox) test for survival curves. *P < 0.05, **P < 0.01, and ****P < 0.0001. Data are represented as means ± SEM